Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus

Sabry, Alaa; Elbasyouni, Sherief Refat; Kalil, Abdalla M.; Abdelrahim, Mahmoud; Mohsen, Tareek; Sleem, Aml

doi:10.1111/j.1440-1797.2006.00573.x

Cited by 10 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Release of proinflammatory cytokines such as tumor necrosis factor a, interferon, and some chemokines have been implicated in the development of atherosclerosis in patients with SLE. 18,19 Also, increased reactive oxygen radicals and apoptosis as well as endothelial dysfunction leads to an accelerated atherosclerotic process in patients with SLE. 20 A high cIMT was reported in patients with SLE 21,22 as in our study.…”

Section: Discussionmentioning

confidence: 99%

Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus

et al. 2016

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology. A major cause of morbidity and mortality in SLE is accelerated atherosclerosis. Endothelial-specific molecule 1 (endocan) is a potential predictor of vascular events and is expressed in response to inflammatory cytokines in endothelial cells. We investigated the relationship between endocan and carotid intima-media thickness (cIMT) as a marker of early atherosclerosis. We included 44 women with SLE and 44 healthy women as controls. Disease severity of SLE was evaluated using the SLE Disease Activity Index. Endocan, C-reactive protein, erythrocyte sedimentation rate (ESR), and lipid panel were measured. The cIMT was 0.70 (range: 0.45-1.20) mm in patients with SLE and 0.40 (0.25-0.60) mm in controls (P < .001). Endocan value was 1.6 ± 0.9 ng/mL in controls and 2.2 ± 1.0 ng/mL in patients with SLE (P = .014). Endocan levels were positively correlated with cIMT (r = .469, P < .001), body mass index (r = .373, P = .013), and ESR (r = .393, P = .008). Endocan level may be associated with subclinical atherosclerosis in SLE. Consequently, endocan levels may be a promising clinical tool for patients with SLE as a guide for preventive strategy.

show abstract

Section: Discussionmentioning

confidence: 99%

Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The SF-36 is a multi-purpose self-administered questionnaire with 36 items that yields eight subscales covering general health, physical function, social function, bodily pain, vitality, physical, mental, and emotional health, as well as two measures of summary scores for the physical (PCS) and mental (MCS) components 14–16 . Using proprietary methods, each sub-scale and summary measure was scored and summed, transformed and normalized with a mean of 50 and one standard deviation (SD) of 10, reflecting that of the general population‥ The SF-36 subscales and summary scores ranged from 0 to 100, with higher scores indicating better outcomes.…”

Section: Methodsmentioning

confidence: 99%

Preoperative Pain and Function: Profiles of Patients Selected for Total Knee Arthroplasty

Nguyen

Ayers

et al. 2016

The Journal of Arthroplasty

View full text Add to dashboard Cite

Background Total knee replacement (TKR) is an effective treatment to relieve pain and restore function in patients with advanced knee osteoarthritis (OA). TKR utilization is growing rapidly, and the appropriateness of current TKR use is of great interest. We examined patient-reported pre-operative pain and function profiles to understand symptom severity at the time of TKR decision. Methods Data were from FORCE-TJR. We included patients undergoing primary, unilateral TKRs between 2011 and 2014 for OA, and had data on the Knee Injury and Osteoarthritis Outcome Score (KOOS) pain and SF-36 Physical Component Summary (PCS) score. We compared patient profiles across groupings by symptoms: 1) little pain-and-high function (KOOS≥70, PCS≥40), 2) little pain-but-poor function (KOOS≥70, PCS<40), 3) high pain-but-high function KOOS<70, PCS≥40), and 4) high pain-and-poor function (KOOS<70, PCS<40). Results Of 6,936 patients, 77% had high pain-and-poor function (Group 4), 19% had high pain or poor function (Groups 2–3), and 5% had little pain-and-high function prior to TKR (Group 1). In Group 1, 86% were constantly aware of their knee problem, 48% reported pain daily yet 5% experienced severe or extreme pain-on-stairs, 1% pain-in-bed. Over half had a lot of limitations in vigorous activities. Compared with Group 4, Group 1 were older, less obese, more educated, and included more men and people reporting being healthy, less disabled, and happy (p<0.05 for all). Conclusion The majority of patients undergoing TKRs had significant pain and/or poor function. Our results provide critical information given the current debate of potentially inappropriate TKR utilization in the US.

show abstract

“…Serum levels of TNFα and of the p55 and p75 type 1 and 2 TNFα receptors are valuable markers of disease activity in patients with SLE, 8 and the serum levels of these is signifi cantly higher in patients with active than inactive disease. [8][9][10] Chloroquine therapy has been shown to signifi cantly lower elevated TNFα levels in SLE patients. 11 Furthermore, TNFα is implicated in the pathogenesis of proliferative lupus nephritis and may cause apoptosis in this setting by triggering TNF receptor types 1 and 2 in the kidney.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus

Hayat

Uppal

2007

Mod Rheumatol

View full text Add to dashboard Cite

Since levels of the proinflammatory cytokine tumor necrosis factor alpha (TNFalpha) are significantly increased in systemic lupus erythematosus (SLE) and may be involved in the disease pathogenesis, we report on the safety and efficacy of infliximab, a chimeric monoclonal antibody directed against TNFalpha, given to a patient with difficult-to-treat active nonrenal SLE. This patient, who failed to remit with full doses of glucocorticoids, hydroxychloroquine, methotrexate, and azathioprine, went into sustained remission with the addition of infliximab infusions. Glucocorticoids could be tapered off completely.

show abstract

Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus

Cited by 10 publications

References 49 publications

Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus

Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus

Preoperative Pain and Function: Profiles of Patients Selected for Total Knee Arthroplasty

Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus

Contact Info

Product

Resources

About